Journal Article Summary
The article investigates the use of GLP-1 receptor agonists, specifically semaglutide and tirzepatide, for managing overweight and obesity among Medicaid members in Massachusetts. This topic is significant because obesity is a major health concern that can lead to various chronic conditions, and understanding how well these medications work in real-world settings is essential for improving treatment strategies. The study aims to provide insights into how long patients stick with these medications and how effectively they help with weight loss over a six-month period.
The researchers conducted a retrospective analysis of claims data from 7,493 MassHealth members who started treatment with either semaglutide or tirzepatide between July and December 2024. They measured persistence, defined as patients not going more than 56 days without a refill, and adherence, which was determined by how many days patients had their medication covered. The findings revealed that about 61% of members continued their treatment, and around 60% adhered to the prescribed regimen. Among a subgroup of patients who were consistent with their treatment, 86.5% achieved at least a 5% reduction in body weight after six months.
Despite these promising results, the study has limitations, including the fact that persistence and adherence rates were lower than those seen in clinical trials. This suggests that while the medications can be effective for weight loss, many patients may struggle to maintain their treatment. Patients should discuss these findings with their healthcare providers to understand potential barriers to treatment adherence and explore strategies to improve their weight management journey.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Meyer Katelyn B., McVeigh Mckenzie, Chiara Ashley N., Boss Kaelyn C., Pomfret Thomas C., Semmel Kyle, Bacon Rachel, Nicolas Diala, et al.. Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population. Journal of Managed Care & Specialty Pharmacy 2026. DOI: 10.18553/jmcp.2026.32.3.271. PMID: 41760563. PMCID: PMC12948758.
Featured Pill Pals Product
Tirzepatide --- 72 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Tirzepatide — 72 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
